IP Library › Granted Patent US 7,105,171
Granted Patent B2
US 7,105,171 · App. 10/094,407 · Granted Sep 12, 2006

Porin B (PorB) as a therapeutic target for prevention and treatment of infection by

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,105,171
App. No.
10/094,407
Granted
Sep 12, 2006
Kind
B2
Abstract

The present invention features peptides of a PorB polypeptide, which PorB peptides are useful in production of antibodies that bind the full-length PorB polypeptide and as a therapeutic agent. In specific embodiments the invention features a composition comprising one or more PorB peptides (other than a full-length PorB polypeptide), which peptides contain at least one epitope that can elicit Chlamydia -neutralizing antibodies. The invention also features methods for induction of a protective immune response against infection by Chlamydia and Chlamydiophila.

Claims (17)

1. A composition comprising:

an isolated C. pneumoniae PorB polypeptide up to 60 amino acids in length wherein the isolated polypeptide contains an amino acid sequence that is at least 67% identical to the amino acid sequence FTNLKFKVRKITSSHRGN (SEQ ID NO: 20), wherein the isolated polypeptide binds to neutralizing C. trachomatis PorB polypeptide-specific antisera; and

a pharmaceutically acceptable carrier.

2. The composition of claim 1 , wherein the isolated polypeptide has the amino acid sequence of FTNLKFKVRKITSSHRGN (SEQ ID NO: 20).

3. The composition of claim 1 , wherein the isolated polypeptide has the amino acid sequence of VLPYLAFSIGSVSRQAPDDSFKKLEDRIFTNLKFKVRKITSSHRGN (SEQ ID NO: 10).

4. The composition of claim 1 , wherein the isolated polypeptide comprises at least 30 amino acids.

5. The composition of claim 1 , wherein the isolated polypeptide comprises at least 20 amino acids.

6. The composition of claim 1 , wherein the isolated polypeptide has the amino acid sequence of FTNFKFKIRKITNFDRVN (SEQ ID NO: 46).

7. The composition of claim 2 , wherein the composition additionally comprises a plurality of polypeptides with different neutralizing PorB polypeptide epitopes of a C. trachomatis.

8. A composition comprising:

an isolated C. pneumoniae PorB polypeptide up to 60 amino acids in length having the amino acid sequence of FTNLKLFKVRKITSSHRGN (SEQ ID NO: 20); and

a pharmaceutically acceptable carrier.

9. The composition of claim 8 , wherein the isolated polypeptide has the amino acid sequence of FTNLKFKVRKITSSHRGN (SEQ ID NO: 20).

10. The composition of claim 8 , wherein the isolated polypeptide has the amino acid sequence of VLPYLAFSIGSVSRQAPDDSFKKLEDRFTNLKFKVRKITSSHRGN (SEQ ID NO: 10).

11. The composition of claim 8 , wherein the isolated polypeptide comprises at least 20 amino acids.

12. The composition of claim 9 , wherein the composition additionally comprises a plurality of polypeptides with different neutralizing PorB polypeptide epitopes of a C. trachomatis.

13. The composition of claim 1 , wherein the isolated polypeptide comprises at least 15 amino acids.

Assignments (1)
EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE Recorded Jul 23, 2008
From: UNIVERSITY OF CALIFORNIA BERKELEY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021282/0982 →